Hologic, Inc. (NASDAQ:HOLX) Position Lessened by Natixis Advisors LLC

Natixis Advisors LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 314,046 shares of the medical equipment provider’s stock after selling 24,878 shares during the quarter. Natixis Advisors LLC’s holdings in Hologic were worth $22,639,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of HOLX. FMR LLC raised its holdings in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB grew its position in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after purchasing an additional 544,889 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Hologic during the fourth quarter worth about $27,007,000. Swedbank AB grew its position in Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after buying an additional 306,562 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after buying an additional 238,222 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

NASDAQ:HOLX opened at $61.82 on Tuesday. Hologic, Inc. has a 1 year low of $59.55 and a 1 year high of $84.67. The firm has a 50 day moving average of $66.94 and a 200-day moving average of $74.51. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $13.87 billion, a P/E ratio of 19.50, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent research reports. Citigroup decreased their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Morgan Stanley cut their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Stephens restated an “overweight” rating and set a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Finally, Evercore ISI cut their price target on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.